Abstract: Murine neuroblastoma cells (clone N 1 E-115) possess neurotensin receptors that mediate cyclic GMP synthesis. Because of the hypothesized relationship between phospholipid metabolism, intracellular Ca2+, and cyclic GMP synthesis, we determined with these cells the effects of neurotensin on 32P labeling of phospholipids, release of inositol phosphates, and intracellular Ca2+ (as determined with the use of Quin-2, a fluorescent probe sensitive to free Ca2+ levels). Neurotensin stimulated incorporation of "P into phospholipids, especially phosphatidylinositol and phosphatidate. Neurotensin is a basic tridecapeptide (pGlu-LeuTyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) that is localized in a wide range of CNS and peripheral tissues and has been shown to be implicated in a variety of physiological processes (Nemeroff and Prange, 1982; Goedert, 1984) . Neurotensin-like immunoreactivity has been demonstrated in nerve terminals (see Uhl, 1982; Kahn et al., 1982) and neurotensin receptors have been localized in regions of the CNS (Uhl, 1982; Kanba et al., 1986) . Neurotensin was recently shown to stimulate cyclic GMP formation and inositol phospholipid hydrolysis (Goedert et al., 1984) in rat brain, confirming the existence of functional receptors for this peptide in the mammalian CNS.
Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) that is localized in a wide range of CNS and peripheral tissues and has been shown to be implicated in a variety of physiological processes (Nemeroff and Prange, 1982; Goedert, 1984) . Neurotensin-like immunoreactivity has been demonstrated in nerve terminals (see Uhl, 1982; Kahn et al., 1982) and neurotensin receptors have been localized in regions of the CNS (Uhl, 1982; Kanba et al., 1986) . Neurotensin was recently shown to stimulate cyclic GMP formation and inositol phospholipid hydrolysis (Goedert et al., 1984) in rat brain, confirming the existence of functional receptors for this peptide in the mammalian CNS.
GMP synthesis . Data from binding studies with radiolabeled neurotensin correlate well with measurements of cyclic GMP response for neurotensin as well as for several structural analogs of this peptide (Gilbert et al., 1986) . Since it has been reported that many of the receptors that stimulate cyclic GMP formation also are effective in the activation of inositol phospholipid turnover (Berridge, 198 l) , we investigated the effect of neurotensin on inositol phospholipid metabolism and on Ca2+ mobilization (as measured with Quin-2) in N 1E-1 15 cells.
MATERIALS AND METHODS
Neuroblastoma clone N 1E-1 15 is a widely studied neuronal clone that possesses a neurotensin receptor that mediates the stimulation of intracellular cyclic
Cell culture
Murine neuroblastoma cells (clone N 1 E-I 15) were cultured in medium I consisting of Dulbecco's modified Eagle's NEUROTENSIN, PHOSPHOLIPIDS, A N D Ca2' 1215 medium (GIBCO, Grand Island, NY, U.S.A.) without antibiotics and supplemented with 10% (vol/vol) fetal bovine serum (GIBCO). Cells (subculture numbers 9-16) were grown for 10-2 1 days in 20 ml of medium I in 75-cm2/250-ml tissue culture flasks (Corning Glass Works, Corning, NY, U.S.A.) in an atmosphere of 10% c02/90% humidified air at 37°C. Subculture was achieved by aspirating medium I, and detaching the cells by incubation in modified Puck's D1 solution followed by centrifugation of the cell suspension for 2 min at 300 g. The supernatant was removed and the cells resuspended in 10 ml of medium I which was then inoculated into flasks to give 4-8 X lo5 cells/flask on day 0. The culture medium was changed on days 4 and 6 and daily thereafter by addition of 10 ml of fresh medium I and removal of 10 ml of medium I.
Cell labeling with 32P and lipid extraction
Cells were isolated from tissue culture flasks in modified Puck's D1 solution as described above. The cells were pelleted by centrifugation (300 g, 2 rnin), the supernatant aspirated, and the cell pellet washed twice in phosphate-free physiological saline solution (solution I) of the following composition: I42 mMNaC1, 5.6 mM KCl, 1 .O mM MgCI2, 2.2 mM CaC12, 3.6 mM NaHC03, 30 m M N-2-hydroxyethylpiperazine-"-2-ethanesulfonic acid (HEPES), I 1.2 mM glucose. Solution I was adjusted before use to pH 7.4 and 340 mOsmol. On resuspension in solution I, viable cells were enumerated by trypan blue dye exclusion. The cells were then diluted in solution I to about 800,000 cells/ml and distributed in 350-pl portions into 10 X 75 mm plastic test tubes containing [32P]orthophosphate (carrier-free, Amersham, Arlington Heights, IL, U.S.A.) and neurotensin (Boehringer Mannheim Biochemicals, Indianapolis, IN, U.S.A.) in a final reaction volume of 500 pl at 37°C. The reactions were terminated after an incubation of 30 rnin with agonist by transferring the contents of each tube to a 16 X 125 mm glass test tube containing 1.5 ml of chloroform/methanol(1:2, vol/vol). The tubes were stored on ice for 30-60 min, after which time 0.5 ml of 2.4 A 4 HCI and 1 .O ml of chloroform were added. The tubes were vigorously vortex-mixed for 20-30 s and the phases separated by centrifugation. The chloroform layer was removed with a Pasteur pipet, and the aqueous layer and cell debris were extracted with an additional 1 .O ml of chloroform. After centrifugation, the chloroform layers were combined and washed with 2.25 ml of water/methanol/2.4 M HCl (I: I: 0.25). The tubes were vortex-mixed and centrifuged, and the aqueous (upper) layer was aspirated and discarded. The volume of the chloroform layer was measured and a portion (50-200 pl) was counted to estimate recovery following TLC. The remaining chloroform layer was evaporated under a stream of nitrogen and mild heating. The residue was redissolved in 80 p1 of chloroform/methanol(2: I) and spotted onto TLC plates (Merck, Darmstadt; silica gel 60, 20 X 20 X 0.025 cm) that had previously been run in a solution containing 1.2 g potassium oxalate in 40 ml of methanol and 60 ml of water, then activated immediately before use by heating for 15 rnin at 1 10°C. Separation of the phospholipids was achieved by developing the plates in one dimension for 1-1 .5 h in chloroform/acetone/methanol/glacial acetic acid/water (40: 15: 13: 12:7). After TLC, the labeled phospholipids were localized by autoradiography with the use of Kodak XRP-5 film (exposure time approximately 16 h). For quantitation, the areas on the TLC plates corresponding to lipids of interest were scraped and counted for radioactivity. The data for phosphatidate (PA), phosphatidylinositol (PI), phosphatidylinositol 4-phosphate (PIP), and phosphatidylinositol4,5-bisphosphate (PIP2) were corrected for recovery of total lipids before analysis.
Assay for the release of [3Hi]inositol phosphates
Confluent cells in one flask (250-m1/75-cmz) were collected as described above, washed, and suspended in 2 ml of solution 11, consisting of I10 mMNaC1, 5.3 mMKC1, I .8 mM CaClz, 1.0 mM MgCI2, 2.0 mM Na2HP04, 25 mM glucose, and 70 mM sucrose (pH 7.35 and 340 mOsmol) to which was added 50 pCi rny~-[~H]inositol ( I 5 Ci/mmol; American Radiolabelled Chemicals, St. Louis, MO, U.S.A.). This suspension was then incubated for 60 min at 37°C in a shaking water bath. At the end of this incubation period, cells were centrifuged and the supernatant was aspirated to remove excess radiolabel. The cells were then suspended in solution I1 to give about 6 X lo5 cells/ml. Aliquots of 2 10 pl of this suspension were added to glass tubes ( 1 3 x 100 mm) containing 30 pl of 100 mM LiCl and incubated at 37°C in a shaking water bath. After a 30-min equilibration period, neurotensin in 60 pl of solution I1 was added and after 10 min, the reaction was stopped with the addition of 750 p1 of chloroform/methanol(l:2). Each tube was then vortex-mixed and placed on ice. The phases were formed by the addition of 250 pl of chloroform and 250 pl of an aqueous solution containing ~-myo-[ ''C]inositol I-phosphate (about 0.7 nCi, 55 mCi/mmol; Amersham) as an internal standard. After further vortex-mixing, the tubes were centnfuged at about 400 g for 5 min. A portion (600 pl) of the upper phase was transferred to a polystyrene (12 X 75 mm) tube that contained 2 ml of water. This solution was then applied to an AG 1-X8, 100-200 mesh, column (0.6 X 1.0 cm; converted to the formate form; Bio-Rad Laboratories, Richmond, CA, U.S.A.) and the inositol phosphates were eluted as described by Bemdge et al. (1983) . Thus, to this column was added 20 ml of 60 mM ammonium formate/5 mMsodium tetraborate, and the eluate was discarded. Total [3H]inositol phosphates were then eluted with 4 ml of I M ammonium forrnate/lOO mM formic acid. The eluate was combined with 16 ml of Safety Solve (RPI, Mount Prospect, IL, U.S.A.) and the radioactivity was determined by liquid scintillation spectrometry. Data were analyzed by computer and corrected for recovery of [14C]inositol I-phosphate which was about 50%.
Quin-2 loading and measurement of [Ca2+Ii
Cells were isolated as described above, resuspended in solution I ( 1 X 10' cells/ml; total volume 7-8 ml), and incubated with Quin-2 acetoxymethyl ester (Calbiochem-Behring; 50 p M ) for 30 rnin at 37°C in a shaking water bath.
The cells were then diluted threefold and allowed to incubate 15-30 rnin longer at 37°C. After gentle centrifugation (300 g, 2 rnin), the supernatant was removed, and the cells were resuspended in fresh solution I ( I X lo6 cells/ml) and kept at room temperature. Immediately before use, a I-ml portion of the cellular suspension was centrifuged, the supernatant was removed, and the pellet was resuspended in fresh solution I to remove any extracellular Quin-2. Fluorescence measurements were made at 37°C with constant stirring in an Aminco-Bowman Spectrophotofluorometer (American Instruments, Silver Springs, MD, U.S.A.); excitation 339, emission 490 nm. Quantitation of calcium concentrations in intact cells was camed out as described by Tsien et al. (1982) .
RESULTS

Stimulation of [32P]inositol lipid labeling by neurotensin
When neuroblastoma cells were incubated under conditions in which neurotensin was added at the beginning of the incubation period together with 32P (carrier-free), there was a substantial increase in the amount of 32P localized in PI and PA (Table 1) . Relatively minor changes were observed in PIP and PIP2 (Table 1) whereas no alterations in the labeling of the quantitatively major phospholipids (phosphatidylethanolamine, -choline, and -serine) were found (data not shown).
Stimulation of the release of [3H]inositol phosphates by neurotensin
The above results indirectly indicated that neurotensin stimulated the cleavage of inositol phosphates from phospholipids of N 1 E-1 15 cells. To obtain direct evidence for this mechanism, we tested the capacity of neurotensin to stimulate the release of [3H]inositol phosphates from cells that had been prelabeled with rny~-[~H]inositol. Neurotensin rapidly stimulated this release, with peak responses occurring by about 2 min (Fig. 1) . Dose-response curves for neurotensin and release of [3H]inositol phosphates (Fig. 2) yielded an ECS0 * SEM = 0.9 f 0.6 nM(n = 4) for this peptide.
Neurotensin at a maximal concentration (lo-' M ) increased release of [ 3H]inositol phosphates over basal in the range of 50% at an incubation time with agonist of 10 min.
Effects of neurotensin on [Ca2+Ii
Receptors that stimulate the turnover of inositol phospholipids also increase the intracellular concentration of Ca2+. With the use of Quin-2, a calciumsensitive fluorescent probe (Tsien et al., 1982) , we found that neurotensin caused an increase in intracellular Ca2+ (Figs. 3 and 4) . Mean basal [Ca2+Ii f SEM was 134 k 7 nM(n = 17) and the ECS0 for neurotensin determined from a dose-response experiment (Fig. 4) was about 4 nM. Repeated addition of LO nM or lower concentration elicited a reproducible elevation in [Ca2+Ii (Fig. 3) . A 10-fold higher concentration of the peptide caused a rapid desensitization of the neurotensin receptor.
DISCUSSION
These data show that neurotensin, presumably by activating its receptors on clone N1E-115, stimulated inositol phospholipid metabolism and increased [Ca2+Ii with similar dose-response profiles. Pre- ' De novo phospholipid labeling was camed out for 30 min as described in Materials and Methods. The radioactivity in the lipids shown accounts for 80-85% of the total radioactivity in the lipid extract. Values given are the X k SEM of four separate experiments. p < 0.0 1 compared to control. viously, we showed that neurotensin acting on N1 E-115 cells and on rat brain slices also mediates cyclic GMP synthesis Gilbert et al., , 1986 , the first known biochemical event associated with neurotensin receptors. In addition, Goedert et al. ( 1 984) showed that neurotensin stimulates the release of inositol phosphate in rat brain slices. All these data support the hypothesis that this tridecapeptide serves as a neurotransmitter or neuromodulator in the nervous system.
As is the case for the effects of a diverse group of agents, the effects of neurotensin on its receptor appear to result in the breakdown of inositol lipids and mobilization of Ca" as early events (Berridge and Irvine, 1984) . In N 1 E-1 1 5 cells neurotensin stimulated labeling of 32Pi primarily into PA and PI (Table 1) . These data suggest that, as in other tissues, breakdown of polyphosphoinositides precedes stimulated label- (Figs. 2 and 4) . Since the KD for [3H]neurotensin and its receptors on these cells is 1 1 nM at 0°C (Gilbert et al., 1986) and the ECso for stimulation of intracellular cyclic GMP formation is 1.5 nM, these events appear to be mediated by the same receptor site and may constitute early consequences of neurotensin receptor activation.
Of interest is the relationship between the release of inositol phosphates, the rise in intracellular Ca2+, and the increased synthesis of cyclic GMP. It has long been hypothesized that increased intracellular Ca2+ stimulates guanylate cyclase, the enzyme that synthesizes cyclic GMP from GTP 198 1) . Some of the evidence in support of a direct role for (.a2+ in receptor-mediated cyclic GMP synthesis is that this response is absolutely dependent on the presence of extracellular Ca2+, and guanylate cyclase in these cells is largely a soluble enzyme and is stimulated by this cation (Bartfai et al., 1978) . In addition, our results showing that receptor-mediated inositol phosphate release in clone N 1 E-1 15 cells is also dependent on extracellular Ca2+ (Forray et al., manuscript in preparation) suggests a link between release of inositol phosphates, Ca2+ mobilization, and cyclic GMP synthesis.
However, previously we proposed (Snider et al., 1984) that neurotransmitters mediate cyclic GMP synthesis by stimulating the release of arachidonic acid from phospholipids (possibly by activating phospholipase A*) followed by the metabolism of arachidonic acid by lipoxygenase(s) to a product that stimulates guanylate cyclase. Thus, for example, eicosatetraynoic acid (ETYA), a lipoxygenase inhibitor, blocks receptor-mediated cyclic GMP synthesis in clone NlE-115 cells (Snider et al., 1984) , but has little effect on receptor-mediated release of inositol phosphates in these cells (McKinney and Richelson, 1986 ). Therefore, it is likely that release of inositol phosphates and the probable subsequent rise of [Ca2+li are not sufficient for receptor-mediated cyclic GMP synthesis.
In conclusion, our data show that the neurotensininduced increases of [3H]inositol phosphates, intracellular Ca2+, and cyclic GMP all occurred within a similar time frame and with similar dose-response curves. However, we can draw no inference yet from these studies as to the sequential or causative relationships of these events.
